[go: up one dir, main page]

BRPI0508254A - métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos - Google Patents

métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos

Info

Publication number
BRPI0508254A
BRPI0508254A BRPI0508254-4A BRPI0508254A BRPI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A BR PI0508254 A BRPI0508254 A BR PI0508254A
Authority
BR
Brazil
Prior art keywords
compositions
cox
combination
psychiatric disorders
treating
Prior art date
Application number
BRPI0508254-4A
Other languages
English (en)
Inventor
Diane Stephenson
Duncan P Taylor
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0508254A publication Critical patent/BRPI0508254A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

MéTODOS E COMPOSIçõES PARA O TRATAMENTO OU PREVENçãO DE DISTúRBIOS PSIQUIáTRICOS COM INIBIDORES DE COX-2 SOZINHOS E EM COMBINAçãO COM AGENTES ANTIDEPRESSIVOS A presente invenção se refere a um método inédito de tratamento e/ou prevenção de distúrbios psiquiátricos em um paciente pela administração ao paciente de pelo menos um inibidor de Cox-2, sozinho ou em combinação com um ou mais agentes antidepressivos. São também descritas composições, composições farmacêuticas e kits.
BRPI0508254-4A 2004-03-02 2005-03-02 métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos BRPI0508254A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54928104P 2004-03-02 2004-03-02
PCT/US2005/006818 WO2005084654A2 (en) 2004-03-02 2005-03-02 Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents

Publications (1)

Publication Number Publication Date
BRPI0508254A true BRPI0508254A (pt) 2007-07-24

Family

ID=34919463

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508254-4A BRPI0508254A (pt) 2004-03-02 2005-03-02 métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos

Country Status (5)

Country Link
EP (1) EP1725222A2 (pt)
JP (1) JP2007526328A (pt)
BR (1) BRPI0508254A (pt)
CA (1) CA2556380A1 (pt)
WO (1) WO2005084654A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0516000A (pt) * 2004-10-15 2008-05-06 Pfizer uso de um composto ou de um sal, solvato, hidrato ou isÈmero óptico farmaceuticamente aceitável do mesmo, método para tratar distúrbio bipolar em um mamìfero em necessidade do mesmo, e, kit para uso no tratamento de distúrbios bipolares
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
EA014820B1 (ru) * 2006-04-04 2011-02-28 Эмодис Гмбх Применение композиций, содержащих антагонист каппа-опиоидных рецепторов бупренорфин, для лечения эмоционально неустойчивых расстройств личности
CN101878042B (zh) 2007-11-28 2013-06-19 尼克塔治疗公司 低聚物-三环共轭物
FR2935611B1 (fr) * 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
GB0822077D0 (en) * 2008-12-03 2009-01-07 Minster Res Ltd Novel treatments
JP6051466B2 (ja) * 2011-10-18 2016-12-27 ラクオリア創薬株式会社 医薬組成物
WO2013179153A1 (en) * 2012-05-10 2013-12-05 Mahesh Kandula Compositions and methods for treatment of neurological degenerative disorders and neurological diseases
GB201416017D0 (en) * 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
WO2017213977A1 (en) * 2016-06-07 2017-12-14 Mehra Akhil Methods and compositions for the treatment of trauma and stressor-related disorders
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
RU2764443C2 (ru) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен
BR112019027037B1 (pt) 2017-06-26 2022-04-05 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico contendo asenapina e polímero híbrido acrílico de silicone, e processo para fabricar uma camada contendo asenapina para uso no referido sistema
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
WO2019060729A1 (en) * 2017-09-21 2019-03-28 Tremeau Pharmaceutials, Inc. INGREDIENTABLE PRODUCT AND METHOD OF USE THEREOF
CN112118838A (zh) 2017-12-05 2020-12-22 赛诺维信制药公司 非外消旋混合物及其用途
CN118955352A (zh) 2017-12-05 2024-11-15 赛诺维信制药公司 晶体形式及其制备方法
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US11648213B2 (en) 2018-06-20 2023-05-16 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4205577B2 (ja) * 2001-06-19 2009-01-07 ミュラー，ノルベルト 精神分裂病、妄想障害、情動障害、自閉症またはチック障害の治療のためのｃｏｘ−２阻害薬の使用

Also Published As

Publication number Publication date
JP2007526328A (ja) 2007-09-13
WO2005084654A3 (en) 2005-11-17
CA2556380A1 (en) 2005-09-15
WO2005084654A2 (en) 2005-09-15
EP1725222A2 (en) 2006-11-29

Similar Documents

Publication Publication Date Title
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
NI200900106A (es) Inhibidores de la actividad de la akt.
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
IL195030A (en) Dpp iv inhibitor formulations
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
ECSP077980A (es) Inhibidores de la actividad akt
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
NO20083836L (no) N-hydroksyakrylamidforbindelser
ATE548034T1 (de) Pharmazeutische zusammensetzungen mit droxidopa
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
TW200507840A (en) Method of treating multiple myeloma
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
NO20091495L (no) Pyrazolopyrimidinderivat
DOP2007000073A (es) Compuestos para tratar la hipertensión pulmonar

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.